Literature DB >> 24900015

Clinical Significance of F-18 FP-CIT Dual Time Point PET Imaging in Idiopathic Parkinson's Disease.

Jin Kyoung Oh1, Ik Dong Yoo1, Ye Young Seo1, Yong An Chung2, Ie Ryung Yoo1, Sung Hoon Kim1, In Uk Song3.   

Abstract

PURPOSE: The purpose of this study was to investigate the diagnostic value of dual time point F-18 FP-CIT PET imaging in idiopathic Parkinson's disease (PD).
MATERIALS AND METHODS: Twenty-four patients with PD (mean age 69.6) and 18 healthy people (mean age 70.26) underwent two sequential PET/CT scans (dual time point imaging) at 90 and 210 min after F-18 FP-CIT injection. Tracer activity of region of interest was measured in the caudate, putamen and a reference region in the brain from both time points. The outcome parameter was the striatooccipital ratio (SOR). Normal SOR values were obtained in the control group. The percent change in tracer activity between 90- and 210-min images was calculated. The SOR values and the percent change in tracer activity were compared between the patients and healthy control group.
RESULTS: The SOR values for the caudate, anterior and posterior putamen at both 90- and 210-min images were significantly reduced in the patients with PD. The lowest P value was obtained for the anterior and posterior putamen (p < 0.001) at both time points. There were significant differences of the percent change in tracer activity for the anterior and posterior putamen in the two groups (p = 0.01).
CONCLUSIONS: F-18 FP-CIT PET scans at 90 and 210 min after injection are both able to diagnose PD. Therefore, the 90-min image by itself is sufficient for diagnosing PD.

Entities:  

Keywords:  Dual time point; F-18 FP-CIT PET; Parkinson’s disease

Year:  2011        PMID: 24900015      PMCID: PMC4043056          DOI: 10.1007/s13139-011-0110-z

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  16 in total

1.  Imaging of dopamine transporters in humans with technetium-99m TRODAT-1.

Authors:  H F Kung; H J Kim; M P Kung; S K Meegalla; K Plössl; H K Lee
Journal:  Eur J Nucl Med       Date:  1996-11

2.  Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.

Authors:  J Booij; J B Habraken; P Bergmans; G Tissingh; A Winogrodzka; E C Wolters; A G Janssen; J C Stoof; E A van Royen
Journal:  J Nucl Med       Date:  1998-11       Impact factor: 10.057

3.  Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

Authors:  P K Morrish; J S Rakshi; D L Bailey; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

4.  Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging.

Authors:  W Pirker; S Asenbaum; M Hauk; S Kandlhofer; J Tauscher; M Willeit; A Neumeister; N Praschak-Rieder; P Angelberger; T Brücke
Journal:  J Nucl Med       Date:  2000-01       Impact factor: 10.057

5.  Quantification of dopamine transporter binding using [18F]FP-beta-CIT and positron emission tomography.

Authors:  Maqsood Yaqub; Ronald Boellaard; Bart N M van Berckel; Mirthe M Ponsen; Mark Lubberink; Albert D Windhorst; Henk W Berendse; Adriaan A Lammertsma
Journal:  J Cereb Blood Flow Metab       Date:  2006-12-27       Impact factor: 6.200

6.  Effects of age on dopamine transporters in healthy humans.

Authors:  P D Mozley; P D Acton; E D Barraclough; K Plössl; R C Gur; A Alavi; A Mathur; J Saffer; H F Kung
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

7.  Functional brain imaging in pure akinesia with gait freezing: [18F] FDG PET and [18F] FP-CIT PET analyses.

Authors:  Hee K Park; Jae S Kim; Ki C Im; Seung J Oh; Mi J Kim; Jae-Hong Lee; Sun J Chung; Myoung C Lee
Journal:  Mov Disord       Date:  2009-01-30       Impact factor: 10.338

8.  Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.

Authors:  Rong Tian; Minggang Su; Ye Tian; Fanglan Li; Lin Li; Anren Kuang; Jiancheng Zeng
Journal:  Skeletal Radiol       Date:  2009-02-10       Impact factor: 2.199

9.  Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls.

Authors:  S A Eshuis; P L Jager; R P Maguire; S Jonkman; R A Dierckx; K L Leenders
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-27       Impact factor: 9.236

10.  Dosimetry of the dopamine transporter radioligand 18F-FPCIT in human subjects.

Authors:  William Robeson; Vijay Dhawan; Abdel Belakhlef; Yilong Ma; Von Pillai; Thomas Chaly; Claude Margouleff; David Bjelke; David Eidelberg
Journal:  J Nucl Med       Date:  2003-06       Impact factor: 10.057

View more
  3 in total

1.  Feasibility of PET Template-Based Analysis on F-18 FP-CIT PET in Patients with De Novo Parkinson's Disease.

Authors:  Eugene Jeong; Sun Young Oh; Kisoo Pahk; Chan-Nyoung Lee; Kun-Woo Park; Jae Sung Lee; Gi Jeong Cheon; Jae Gol Choe
Journal:  Nucl Med Mol Imaging       Date:  2013-03-26

2.  Validation of Simple Quantification Methods for (18)F-FP-CIT PET Using Automatic Delineation of Volumes of Interest Based on Statistical Probabilistic Anatomical Mapping and Isocontour Margin Setting.

Authors:  Yong-Il Kim; Hyung-Jun Im; Jin Chul Paeng; Jae Sung Lee; Jae Seon Eo; Dong Hyun Kim; Euishin E Kim; Keon Wook Kang; June-Key Chung; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2012-08-02

3.  Diagnostic Performance for Differential Diagnosis of Atypical Parkinsonian Syndromes from Parkinson's Disease Using Quantitative Indices of 18F-FP-CIT PET/CT.

Authors:  Miju Cheon; Seung Min Kim; Sang-Won Ha; Min Ju Kang; Hea-Eun Yang; Jang Yoo
Journal:  Diagnostics (Basel)       Date:  2022-06-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.